原代软骨细胞专用培养基
软骨细胞专用培养基由abiowell技术团队精心筛选验证,经过长期测试,本产品可保持软骨细胞最佳的生长状态。本产品中已包含软骨细胞生长所需的各种成分,无需额外添加任何成分,可直接用软骨细胞的体外培养。
01产品图片

02产品简介
软骨细胞专用培养基由abiowell技术团队精心筛选验证,经过长期测试,本产品可保持软骨细胞最佳的生长状态。本产品中已包含软骨细胞生长所需的各种成分,无需额外添加任何成分,可直接用软骨细胞的体外培养。
03产品介绍
软骨细胞专用培养基由abiowell技术团队精心筛选验证,经过长期测试,本产品可保持软骨细胞最佳的生长状态。本产品中已包含软骨细胞生长所需的各种成分,无需额外添加任何成分,可直接用软骨细胞的体外培养。
培养基成分软骨细胞基础培养基+1%软骨细胞添加剂+5%FBS+1%双抗细菌检测阴性真菌检测阴性支原体检测阴性细胞生长试验效果形态正常,生长良好运输条件冰袋冷藏运输存储条件2℃-8℃,避光储存有效期3个月供应限制仅供科研使用
认真做好每一个抗体, 每一个抗体都经过反复验证!
Journal of Functional Biomaterials IF:5.9 Authors:Zihan Zhu, Ming Ju, Min Li, Wangang Zhang Authors:Yao Bo, Wan Li, Deng Jia, Chen Zhengyu, Zhao Lei, Wang Weiguo, Han Ziwei
Platelet-rich plasma (PRP) has been shown to be beneficial to Frozen shoulder (FS), but the mechanism of PRP's intervention in FS is still incomplete. Ferroptosis and inflammation are important pathological factors of cartilage injury, but their role in FS has not been explored. In vivo , we found that PRP treatment significantly enhanced the joint range of motion and mitigated joint histopathological damage in FS rats. Notably, levels of iron ions, the ferroptosis marker prostaglandin-endoperoxide synthase 2 (PTGS2), reactive oxygen species (ROS), malondialdehyde (MDA), and pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) in the cartilage tissue of PRP-treated rats were significantly reduced. Conversely, levels of superoxide dismutase (SOD) and glutathione (GSH) were markedly increased. In vitro experiments revealed that PRP effectively countered the IL-1β-induced suppression of chondrocyte proliferation while also reducing levels of ferroptosis and inflammation. Furthermore, the CST1/GPX4 pathway was suppressed in the FS environment, while it has the potential to be activated by PRP. Importantly, silencing CST1 negated the therapeutic effects of PRP on IL-1β-treated chondrocytes and FS rats. In summary, we found that PRP alleviated the progression of FS by inhibiting ferroptosis and the inflammatory response by activating the CST1/GPX4 signaling pathway
Authors:Zihao Ren, Zhen Hu, Yun Zhou, Guangqing Cai, Shengwen Xiang, Zhijiang Ao, Weiguo Hu, Xing Li, Licheng Wei IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL IF:1.7
The molecular mechanisms underlying growth hormone (GH) therapy in children with idiopathic short stature (ISS) remain incompletely understood. This study investigated how GH promotes bone growth in children with ISS, focusing on insulin-like growth factor-binding protein 2 (IGFBP2) and thrombospondin-1 (THBS1). Analysis of ISS patient plasma showed downregulated IGFBP2, predicted to interact strongly with THBS1. Experiments using human chondrocytes revealed that GH treatment stimulated cell proliferation, accelerated the cell cycle, and induced hypertrophic differentiation, marked by increased expression of proteins like COL10A1, RUNX2, OCN, OPN, and alkaline phosphatase activity. GH also elevated IGFBP2 and insulin-like growth factor-1 (IGF-1) while suppressing THBS1. Crucially, knocking down IGFBP2 blocked these GH effects, reducing proliferation, halting cell cycle progression, decreasing differentiation markers and IGF-1, while increasing THBS1. Conversely, overexpressing IGFBP2 mimicked GH's effects. Importantly, silencing IGFBP2 partially prevented GH-induced proliferation, differentiation, and IGF-1 secretion. This demonstrates that IGFBP2 acts as a key mediator of GH's action by inhibiting THBS1, which subsequently activates the IGF-1 pathway to drive chondrocyte proliferation and hypertrophic differentiation. The IGFBP2-THBS1 axis is thus a core mechanism for GH therapy in ISS, offering a novel therapeutic target for improving treatment.
AML12细胞专用培养基由abiowell技术团队精心筛选验证,经过长期测试,本产品可保持AML12细胞最佳的生长状态。本产品中已包含AML12细胞生长所需的各种成分,无需额外添加任何成分,可直接用于AML12细胞的体外培养。
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2016 年
- 所在地
- 湖南
- 收录条目
- 498 个
- 平台核验
- 平台代管
06品牌与供应商
公司产品涵盖抗体、细胞、培养基、质粒载体等多个领域,致力于为生命科学研究提供可靠的工具与解决方案。自创立以来,艾碧维始终秉持“求实、诚挚、勤勉、克己”的发展理念,坚持以自主研发与持续创新为核心动力。公司拥有百余人的团队,其中硕士及以上学历生物医学专业人才占比超过30%,包括博士4人,构建起一支结构合理、专业扎实的研发与服务队伍。通过设立研发部、生产部、市场与营销部、财务部等多功能部门,公司实现了从产品开发到市场推广的全流程管控。艾碧维不仅敢于质疑现状,积极为生命科学家突破技术壁垒提供支撑,更注重与客户的深度互动与合作,通过持续收集反馈、开展研发协作,提前预见并解决潜在问题。未来,公司将继续秉持“助力科研创新,让实验更简单”的使命,一步一个脚印地打造具有国际领先水平的技术研发与产业化平台,为全球生命科学领域的进步持续赋能。注意: 1.本公司产品仅供科研使用。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
艾碧维 在本目录共 498 个条目,除本条外还有:
科研在线(TeleVM). 原代软骨细胞专用培养基(AW-MC018)[EB/OL]. 产品目录, 2026-10-31. https://www.suprotek.cn/products/item/aw-mc018.html.
TeleVM. (2026, October 31). 原代软骨细胞专用培养基(AW-MC018). 产品目录. https://www.suprotek.cn/products/item/aw-mc018.html
@misc{biocsp_item_aw_mc018,
title = {原代软骨细胞专用培养基(AW-MC018)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-10-31,产品目录},
url = {https://www.suprotek.cn/products/item/aw-mc018.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源